These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Weber J Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057 [TBL] [Abstract][Full Text] [Related]
3. [The role of co-inhibitory signals driven by CTLA-4 in immune system]. Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421 [TBL] [Abstract][Full Text] [Related]
4. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Wolchok JD; Saenger Y Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145 [TBL] [Abstract][Full Text] [Related]
6. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Peggs KS; Quezada SA; Allison JP Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925 [TBL] [Abstract][Full Text] [Related]
7. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
8. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Agarwala SS Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852 [TBL] [Abstract][Full Text] [Related]
9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. Biburger M; Weth R; Wels WS J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482 [TBL] [Abstract][Full Text] [Related]
10. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. O'Day SJ; Hamid O; Urba WJ Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991 [TBL] [Abstract][Full Text] [Related]
11. CTLA-4: negative regulator of the immune response and a target for cancer therapy. Keilholz U J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542 [TBL] [Abstract][Full Text] [Related]
12. Reversing T-cell Dysfunction and Exhaustion in Cancer. Zarour HM Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739 [TBL] [Abstract][Full Text] [Related]
15. Targeting lymphocyte co-stimulation: from bench to bedside. Felix NJ; Suri A; Salter-Cid L; Nadler SG; Gujrathi S; Corbo M; Aranda R Autoimmunity; 2010 Nov; 43(7):514-25. PubMed ID: 20429850 [TBL] [Abstract][Full Text] [Related]
16. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. Kähler KC; Hauschild A J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648 [TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Pico de Coaña Y; Choudhury A; Kiessling R Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825 [TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
19. Recent advances using anti-CTLA-4 for the treatment of melanoma. Sarnaik AA; Weber JS Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898 [TBL] [Abstract][Full Text] [Related]
20. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. Fenton RG; Turcovski-Corrales SM; Taub DD J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]